BioCardia, Inc.
BCDA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000925741
In the last 90 days, BioCardia, Inc. insiders filed 10 open-market purchases and 0 sales; 21 institutions reported holding it in 13F filings for Q2 2026, worth $1.65M in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding BioCardia, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 26 | 23 | −3 |
| Shares | 2.14M | 1.64M | −501.2K (−23.5%) |
| Value | $3.10M | $3.17M | +$68.0K (+2.2%) |
New holders (1)
Institutions that held BioCardia, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Family Management Corp | 142,186 | $276.0K | 0.07% |
Sold out (4)
Institutions that held BioCardia, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Captrust Financial Advisors | 660,637 | $958.0K |
| Citadel Advisors LLC | 17,675 | $26.0K |
| Cetera Investment Advisers | 12,610 | $18.0K |
| Cutler Group LP | 900 | $1.00K |